CHOSA Oncology AB — Investor Relations & Filings

CHOSA Oncology AB is a biotechnology company focused on advancing precision medicine for platinum-based chemotherapy. The company's strategy integrates diagnostics and therapeutics to personalize patient care. Its primary asset is Platin-DRP®, a patented diagnostic tool that analyzes a tumor's genetic profile to predict its response to cisplatin and carboplatin. This technology aims to improve survival rates and prevent the administration of ineffective, toxic treatments to non-responding patients. Complementing this is LiPlaCis®, a novel drug formulation that delivers cisplatin directly to tumors via a specialized liposome system, designed to enhance efficacy while minimizing side effects. The company's technologies are being validated in various cancers, including lung and breast cancer.